|
Free
Tirzepatide's $12.8B quarter fuels upside but concentrates Lilly's revenue and risk exposure.
|
Free
Lilly leads on efficacy and oral reach, but Novo and pricing loom large.
|
Free
Tirzepatide powers two-thirds of revenue and global share gains, yet concentration risk persists.
|
Free
PCGH's shift to pharma and services shows healthcare rotation amid AI-led tech dominance.
